An exploration of psilocybin use in women with premenstrual dysphoric disorder (PMDD)

The abstract of this exploratory study reads: "This research explores the use of psilocybin in women with PMDD, a condition that has not yet been studied in psychedelic research. The findings suggest potential benefits but highlight the need for further targeted research. This could inform building nuanced and diverse narratives around psychedelic use for various health issues, supporting realistic and balanced public understanding and both clinical and underground practice.  Objective: The study aims to document the experiences of women with PMDD using large doses of psilocybin, to provide an initial step for future research around women’s health.  Methodology: Utilising an exploratory qualitative approach, the study involved semi-structured interviews with 11 participants from diverse demographics, recruited from online platforms. Ethical considerations were addressed, and data analysis involved thematic analysis.  Findings: - Participants often turned to psilocybin after conventional treatments had failed. Long diagnosis times and insufficient care from the health sector calls for systemic change; - Experiences with, and approaches to psilocybin were diverse, with most reporting improved quality of life and reduced symptoms, though this was not without challenges; - Psilocybin use was largely part of broader self-exploration and lifestyle changes. Not a quick-fix option, especially with PMDD symptoms and when trauma is prevalent; - Moderate doses mitigated symptoms with less disruption. Larger doses appeared to hold transformative potential, but with increased risks, particularly with excessive dosage (which limited the ability to understand confronting insights), or when taken without support; and - Becoming self-advocates and taking research and treatment into their own hands supported agency and deeper self-knowledge. Understanding of PMDD emerged as interconnected within a broader cultural context that challenged Western societal norms.  Limitations: Small sample size, selection bias and reliance on retrospective accounts limits the study's generalizability. Though the small sample was demographically diverse.  Recommendations for Future Research: - Understand the specific interplay between PMDD and psilocybin with targeted studies, considering the role and timing of the menstrual cycle beyond anecdotal evidence; - Prioritise minimising harm, risk, and access barriers, particularly for vulnerable women seeking urgent relief and those from underserved communities; and - Investigate the potential for microdosing psilocybin to improve the experience of symptoms of PMDD." There is also a helpful linked Drug Science article Psilocybin shows promise in supporting symptoms of Premenstrual Dysphoric Disorder.

For more psychedelic news and research, visit the psychedelic health professional network homepage.